Dogwood Therapeutics prices $4.8M registered direct offering; funds operations through Q1 2026

Dogwood Therapeutics, Inc.

Sold 578,950 shares at $8.26 each for gross proceeds of approximately $4.8 million.
Proceeds to advance Halneuron clinical development and for working capital.
Offering closed March 14, 2025; Maxim Group LLC acted as sole placement agent.
Company expects cash runway through Q1 2026; Halneuron Phase 2b CINP interim data planned for Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.